BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Delayed-Action Preparations

Below is an extended Delayed-Action Preparations research listing. Click here to return to the Delayed-Action Preparations main in depth entry.

Recent Publications on Delayed-Action Preparations:

Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes.
OBJECTIVE: To assess the efficacy and safety of controlled-release...
Direct Link
4th October, 2008
Davao Doctor's Oncology Center, Davao Doctor's Hospital, Davao City,
Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe postherpetic neuralgia pain.
OBJECTIVE: To evaluate the efficacy and safety of OxyContin...
Direct Link
4th October, 2008
Department of Pain Management, Sino-Japan Friendship Hospital, Beijing, PR
Patient-controlled analgesia versus oral controlled-release oxycodone - are they interchangeable for acute postoperative pain after laparoscopic colorectal surgeries?
BACKGROUND: Standard therapy for postoperative pain after laparoscopic...
Direct Link
4th October, 2008
Mount
Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
OBJECTIVE: To evaluatethe efficacy and safety of OxyContin tablets...
Direct Link
4th October, 2008
Cancer Center of Tongji Hospital, Tongji Medical College, Huazhong
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. 27th September, 2008
Alliance Urology Specialists, Greensboro, NC 27403, USA.
Alginate-chitosan film for ocular drug delivery: effect of surface cross-linking on film properties and characterization. 26th September, 2008
Department of Pharmaceutical Sciences, Guru Jambheshwar University of
The approach to optimizing stroke care.
Stroke is a leading cause of death, disability, and dependence. Treatment...
Direct Link
25th September, 2008
Department of Emergency Medicine, The Warren Alpert School of Medicine of
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic...
Direct Link
25th September, 2008
Miller School of Medicine, University of Miami, Miami, USA.
Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.
BACKGROUND: Efficacy of heparin and low-molecular-weight heparins (LMWHs)...
Direct Link
25th September, 2008
Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS Policlinico
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
PURPOSE: Evaluate the activity of everolimus (RAD001) in combination with...
Direct Link
23rd September, 2008
Department of Gastrointestinal Medical Oncology, Unit 426, The University
Preparation of Carbopol/chitosan interpolymer complex as a controlled release tablet matrix; effect of complex formation medium on drug release characteristics.
Chitosan/Carbopol971NF (poly acrylic acid) interpolymer complexes were...
Direct Link
17th September, 2008
BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, Korea.
In Vitro/in vivo relationship of gabapentin from a sustained-release tablet formulation: a pharmacokinetic study in the beagle dog.
The aim of this study was to examine the in vitro/in vivo relationship of...
Direct Link
17th September, 2008
College of Pharmacy, Sungkyunkwan University, Suwon, Korea.
[Paliperidone--a novel second-generation antipsychotic] 10th September, 2008
Region Hovedstaden Psykiatri, Psykiatrisk Center Glostrup, Glostrup.
Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic...
Direct Link
5th September, 2008
[Long acting insulin analogues: results of clinical studies with insulin glargine]
The insulin treatment in type 2 diabetes mellitus (DM 2) is an explosive...
Direct Link
30th August, 2008
Medizinische Klinik am Universitatsklinikum Tubingen, Abteilung IV.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional